12月25日晚间，深圳市倍轻松科技股份有限公司（688793.SH，以下简称"倍轻松"）发布公告称，公司 及实际控制人马学军因涉嫌信息披露违法违规，收到中国证监会下发的《立案告知书》。根据相关法律 法规，中国证监会决定对公司及马学军立案。 公告发布后，倍轻松股价于12月26日早盘大幅低开，截至收盘，跌14.68%，报22.61元/股，总市值为 19.43亿元。 12月26日，针对公司及实控人被立案、股价下跌等情况，南都湾财社记者致电倍轻松董秘办，其接线人 员表示，将反馈核实一下情况。 实控人占用资金问题频发 上月套现超6400万元 此次立案并非无迹可寻。近年来，倍轻松实控人马学军多次被曝出非经营性资金占用问题。2025年8 月，倍轻松曾发布自查公告，披露实际控制人马学军在2021年10月至2022年期间存在非经营性资金占用 情形，累计占用上市公司资金1208.23万元。 连收监管函 今年前三季度业绩承压 公开资料显示，倍轻松成立于2000年，主要从事智能便携按摩器的设计、研发、生产、销售及服务。 2021年7月，倍轻松在上交所科创板上市，被誉为"智能按摩设备第一股"。 公告显示，马学军通过公司员工借款方式分两 ...

倍轻松公告，公司及子公司北京倍轻松科技开发有限公司收到北京知识产权法院对倍轻松及北京倍轻松 的《民事起诉状》等相关材料。原告大东电机工业株式会社起诉，要求判令被告立即停止侵害涉案发明 专利权的行为，并赔偿经济损失及诉讼费用共计1000万元。公司表示，本次被诉侵权产品非核心产品， 且公司经营正常，未受实质性影响。案件尚未开庭审理，最终结果不确定。 ...

中经记者 秦枭 北京报道 12月19日，《中国经营报》记者注意到，德国慕尼黑第一地区法院就XR行业首例核心技术专利侵权案 作出一审裁决，认定VITURE公司旗下VITURE Pro等产品侵犯XREAL所持欧洲专利 VITURE方面对记者表示，目前除德国外，涉诉产品在其他欧洲国家均正常销售，产品未被禁售，也未 被亚马逊下架。公司会在合法范围内继续销售产品，保护公司和用户的合法权益。 VITURE Pro此次被判侵权的专利则是由XREAL在2019年12月申请的增强现实设备及其所用光学系统相 关技术，该技术直接决定了AR眼镜的显示效果。 XREAL成立于2017年，被称为国内"AR眼镜四小龙"之一，其已构建起覆盖中、美、日、欧的全球化业 务版图。根据IDC数据，自2022年起，XREAL已连续多年稳居全球消费级 AR 市场份额第一。 天使投资人、人工智能专家郭涛对记者表示，对VITURE而言，此次裁决或带来一定的负面影响。其核 心产品VITURE Pro在德国被禁售，可能引发其他海外市场的连锁专利诉讼。资本市场对其增长确定性 和抗风险能力的评估将趋于谨慎，品牌声誉受损严重，即便启动技术整改或上诉，短期内也难以挽回 ...

Core Viewpoint - The ongoing legal disputes between Suoteng Juchuang and Lingming Photon revolve around allegations of technology secret infringement and patent rights, highlighting the competitive tensions in the laser radar and semiconductor industry [2][3][5]. Group 1: Legal Disputes - Suoteng Juchuang filed a lawsuit against Lingming Photon in November, claiming infringement of its self-developed SPAD chip technology secrets [2][5]. - Lingming Photon responded by filing a lawsuit regarding alleged patent infringements related to Suoteng Juchuang's E1 series products [3][4]. - Suoteng Juchuang stated that the core of the dispute is its accusation against Lingming Photon for infringing its technology secrets, while Lingming Photon has not provided a substantial response to these allegations [5][6]. Group 2: Company Backgrounds - Suoteng Juchuang, established in 2014 and headquartered in Shenzhen, is a leading player in the laser radar market with a global market share ranking first, serving over 3,400 clients in robotics and more than 350 automotive manufacturers [5][6]. - Lingming Photon, founded in 2018, specializes in chip design, particularly in SPAD dToF sensor chips, which are critical components in laser radar technology [5][6]. Group 3: Legal Proceedings and Responses - Suoteng Juchuang has initiated legal actions to counter Lingming Photon’s patent lawsuit and plans to utilize legal avenues such as patent invalidation [4][7]. - Both companies have filed multiple lawsuits against each other, with Suoteng Juchuang also pursuing claims of commercial defamation against Lingming Photon for its public statements related to the lawsuits [7].

Core Viewpoint - Lingming Photon has filed a lawsuit against Suoteng Juchuang for alleged infringement of its invention patent rights related to the E1 series products, while Suoteng Juchuang has countered with its own lawsuit regarding the infringement of its technical secrets [2][3]. Group 1: Legal Disputes - Lingming Photon filed a lawsuit on December 17, claiming that Suoteng Juchuang's E1 series products infringe its invention patent rights [2]. - Suoteng Juchuang responded on December 18, stating it would counter the lawsuit through legal means, including a declaration of patent invalidity [2]. - Suoteng Juchuang had previously filed a lawsuit against Lingming Photon in November, accusing it of infringing on its self-developed SPAD chip's technical secrets [2][3]. Group 2: Company Background - Suoteng Juchuang, established in 2014 and headquartered in Shenzhen, holds the largest market share in the global lidar industry and has provided core components and solutions to over 3,400 clients in robotics and more than 350 automotive manufacturers [3]. - Lingming Photon, founded in 2018, specializes in chip design, with its SPAD dToF sensor chips considered essential for lidar technology [3]. Group 3: Evidence and Claims - Suoteng Juchuang claims to have established a complete chain of evidence regarding the alleged infringement of its core technology by Lingming Photon, including analysis of internal documents and technical comparisons [3]. - Lingming Photon previously stated it had not received any legal correspondence and reserved the right to pursue legal action against any actions that could harm its reputation [3]. Group 4: Ongoing Legal Proceedings - Suoteng Juchuang has confirmed that its lawsuits regarding technical secret infringement and invention patent infringement have been accepted by the court, with another patent infringement case currently under review [4]. - In response to Lingming Photon’s public statements and actions related to the lawsuits, Suoteng Juchuang has initiated a commercial defamation lawsuit and filed complaints with market supervision authorities [4].

围绕一款上亿销售额的中成药大单品专利权，两家上市药企的官司有了新进展。 12月14日，华东医药股份有限公司（华东医药，000963）公告称，全资子公司杭州中美华东制药有限公 司（以下简称"中美华东"）于近日收到浙江省高级人民法院送达的《民事判决书》。作为原告，一审判 决驳回中美华东的全部诉讼请求，案件受理费59.8732万元，由中美华东负担。 根据公告，该诉讼涉案金额为1.1亿元，对于这个结果，华东医药在14日的公告中称，将依法向中华人 民共和国最高人民法院提起上诉。 一审判决 结果 来源：华东医药公告 华东医药作为原告发起的诉讼可以追溯至2023年底。彼时，中美华东将青海珠峰冬虫夏草原料有限公司 （简称"珠峰原料"）、青海珠峰冬虫夏草药业有限公司（简称"珠峰药业"）、杭州华东武林大药房有限 公司（简称"武林大药房"）诉至浙江省高级人民法院。 在三个被告中，珠峰药业是浙江佐力药业股份有限公司（佐力药业，300181）的控股子公司，而武林大 药房是华东医药100%控股公司。当时业内有人调侃："华东医药将自己告上了法庭。" 从公开信息来看，华东医药争的是百令系列中成药的专利权。 华东医药拥有百令胶囊这款产品，公开 ...

【#爱旭股份回应在德国被诉专利侵权#】#爱旭股份否认专利侵权#爱旭股份发布声明称，公司关注到有 关媒体报道Maxeon Solar Pte. Ltd.（以下简称 "Maxeon Solar"） 在德国慕尼黑第一地方法院递交一项新 的专利侵权诉讼，指控爱旭及相关公司的ABC产品侵犯其EP2297789专利，经查，该专利与Maxeon Solar在2024年5月16日荷兰法院临时禁令申请中被法院驳回请求的EP2297788专利属于同族专利。经爱 旭的知识产权团队以及合作的欧洲知识产权律师事务所多次核验，特此确认：爱旭ABC产品与其 EP2297789专利技术有着根本的不同，不存在对该专利的侵犯。针对该项诉讼，公司将积极应诉，并与 全球合作伙伴紧密协作，共同捍卫正当权益。公司将及时公布此项诉讼的进展。 ...

【华东医药核心产品专利案一审败诉 涉案金额约1.11亿元】12月14日，华东医药（000963.SZ）公告全 资子公司杭州中美华东制药有限公司（以下简称"中美华东"）于近日收到浙江省高级人民法院送达的民 事判决书，一审判决为：驳回中美华东的全部诉讼请求。案件受理费约59.87万元，由中美华东负担。 以发酵冬虫夏草菌粉为核心成分的百令胶囊为华东医药核心产品之一，原为其独家品种，该产品是一款 发酵冬虫夏草菌粉制剂，功能主治补肺肾、益精气，用于肺肾两虚引起的咳嗽、气喘、咯血、腰背酸痛 等。该产品的主要销售市场在国内城市公立医院、县级公立医院、城市社区中心及乡镇卫生院终端。 米内网数据显示，早在2017年，华东医药旗下百令胶囊销售规模已达到20亿元级别。今年上半年，中美 华东生产的百令胶囊为中国城市社区市场中成药TOP20品牌之一，销售额达1亿元以上。 百令胶囊、百令片同样是佐力药业旗下核心产品。2024年1月，佐力药业收到国家药品监督管理局签发 的百令胶囊注册证，打破华东医药"一家独大"局面。 2025年12月12日，佐力药业亦就与华东医药的诉讼进展进行披露，其在公告中称，近日，公司收到民事 判决书，经法院审理认定 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、案件所处的诉讼（仲裁）阶段：一审判决 2、上市公司所处的当事人地位：原告 3、涉案的金额：111,386,405元（较首次披露暂计金额增加10,600元） 4、对上市公司损益产生的影响：本次诉讼案件尚处于一审判决阶段，对公司本期利润及期后利润不构 成重大影响，公司将依法向中华人民共和国最高人民法院提起上诉，并根据上诉进展情况及时履行信息 披露义务。 华东医药股份有限公司（以下简称"公司"或"本公司"）全资子公司杭州中美华东制药有限公司（以下简 称"中美华东"）于近日收到浙江省高级人民法院送达的《民事判决书》（(2023) 浙知民初3号）。现将 有关事项公告如下： 一、本次诉讼的基本情况 因侵害发明专利权纠纷，中美华东将青海珠峰冬虫夏草原料有限公司、青海珠峰冬虫夏草药业有限公 司、杭州华东武林大药房有限公司三名被告诉至浙江省高级人民法院，详见公司于2024年01月03日在 《证券时报》《中国证券报》《上海证券报》及巨潮资讯网（www.cninfo.c ...

Core Viewpoint - The company Bai'ao Saituo has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, leveraging its "Thousand Mice and Ten Thousand Antibodies" plan and RenMice human antibody platform, but faces multiple risks including reliance on cost-cutting for profitability, high proportion of related-party transactions, patent infringement lawsuits, and significant unremedied losses [1][4]. Group 1: Financial Performance and Cost Management - From 2022 to 2024, Bai'ao Saituo's operating revenue steadily increased, with net profit turning from a loss of 602 million yuan to a profit of 33.54 million yuan, and achieving a net profit of 114 million yuan in the first three quarters of this year [6]. - However, R&D expenses significantly decreased from 699 million yuan to 324 million yuan, and the total number of R&D personnel dropped from 627 to 337, with dedicated R&D staff reduced from 58 to 5 [6]. - The revenue growth of 446 million yuan during the same period contrasts with a decline in R&D expenses of 375 million yuan, raising concerns about whether profitability improvements stem from cost-cutting rather than genuine business growth [6]. Group 2: Related-Party Transactions and Patent Litigation - The antibody development business, a key growth area for Bai'ao Saituo, has a compound annual growth rate of 58.26% from 2022 to 2024, with a gross margin exceeding 80% [7]. - Nearly 30% of the revenue in this segment comes from related parties, specifically from joint ventures such as Doma Pharmaceutical and its subsidiary, contributing a total of 170 million yuan, which accounts for 27.43% of total antibody development revenue [7]. - The core technology platform RenMice faces intellectual property risks, as a lawsuit was filed by He Bo Pharmaceutical in September 2024, alleging patent infringement, which could undermine market confidence in the company's technological independence [7]. Group 3: Unremedied Losses and Debt Concerns - As of the end of 2024, Bai'ao Saituo has accumulated unremedied losses of 1.754 billion yuan, with the company acknowledging the risk of returning to losses if R&D investments remain high or revenue growth does not meet expectations [8]. - The controlling shareholders, Shen Yuele and his wife, face significant debt obligations, needing to repay approximately 129 million yuan from 2025 to 2028, primarily relying on the liquidation of their H-shares in the company [8]. - The total compensation for the company's directors, supervisors, and key technical personnel from 2022 to 2024 reached 61.6072 million yuan, maintaining a high level despite the company's losses, which has raised inquiries from the stock exchange [8].